Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 5609 - 5616 of 12091 results
ML Strategies Health Care Preview - Week of December 3rd
December 3, 2018| Blog| Viewpoint
DOJ Announces to the Supreme Court That it Will Seek to Dismiss False Claims Act Case, and Affirms Position on Materiality Under Escobar
December 3, 2018| Blog| Viewpoint
USCIS Proposes Changes to H-1B Visa Lottery Process
December 3, 2018| Alert| Viewpoint
Anthem Settlement Holds Lessons on Data Breaches, Costs
December 1, 2018| News
How to Compel Arbitration When Litigation Is Commenced in State Court
November 30, 2018| Blog| Viewpoint
Overview of CMS' 1332 Waiver Concepts
November 30, 2018| Blog| Viewpoint
Judge Applies WesternGeco Principles to Direct Infringement Under 35 U.S.C.§ 271(a)
November 30, 2018| Blog| Viewpoint
That Local Representative Problem . . . and the New Guidelines on the Territorial Scope of the GDPR (Part I)
November 29, 2018| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|